Leading the Future of Live Biotherapeutics: Eubacterium spp. Research Services
In the rapidly evolving landscape of the human microbiome, the genus Eubacterium has emerged as a cornerstone of intestinal health and systemic metabolic balance. As a premier Contract Research Organization (CRO) specializing in preclinical development, Creative Biolabs provides the specialized expertise and advanced laboratory infrastructure required to transform these anaerobic giants into the next generation of Live Biotherapeutic Products (LBPs). From strain isolation and functional characterization to complex in vivo disease modeling, our services are designed to bridge the gap between microbiome discovery and clinical reality.
Overview of Eubacterium spp. in Microbiome Therapeutics
The Eubacterium genus comprises a group of Gram-positive, non-spore-forming anaerobic bacteria that are fundamental to the "core microbiome." Unlike transient probiotics, Eubacterium species are permanent residents that drive the trophic chain of the gut. By converting fermentation intermediates like lactate and acetate into high-value short-chain fatty acids (SCFAs), they maintain the acidic environment necessary to inhibit pathogens while providing the primary energy source for colonocytes.
Discover Our Eubacterium Research Specializations
The genus Eubacterium is diverse, with specific species playing unique roles in host physiology. Click the links below to explore our targeted research sub-pages for these key therapeutic candidates:
A metabolic powerhouse known for consuming lactate and acetate to produce butyrate. It is a leading candidate for treating Type 2 Diabetes, insulin resistance, and metabolic syndrome due to its ability to improve glycemic control and gut barrier integrity.
One of the most abundant butyrate-producers in the healthy human gut. Research focuses on its potent anti-inflammatory properties, making it a primary target for therapies addressing Inflammatory Bowel Disease (IBD) and Rheumatoid Arthritis.
A versatile acetogen with unique wood-ljungdahl pathway capabilities. It is currently being investigated for its role in preventing atherosclerosis by demethylating L-carnitine and for its potential to ameliorate ulcerative colitis through bile acid modulation.
Comprehensive Preclinical Research Services
We offer a full suite of end-to-end services tailored specifically for anaerobic Eubacterium research:
Eubacterium barkeri DNA Standard product can be used for quantitative research and analysis, assay development, verification, and validation, and laboratory quality control.
This product contains high-quality, intact genomic DNA isolated from Eubacterium barkeri Genomic DNA. It is a purified and ready-to-use DNA sample, ideal for a wide range of molecular biology applications, including PCR, qPCR, and Next-Generation Sequencing.
Current research is rapidly expanding the therapeutic horizon for Eubacterium strains. Our CRO supports sponsors in exploring the following applications:
Eubacterium hallii has shown remarkable efficacy in preclinical models for increasing insulin sensitivity. By modulating the bile acid pool and increasing GLP-1 secretion, these strains are being developed as "next-gen" treatments for obesity and metabolic dysfunction.
Eubacterium rectale serves as a critical regulator of the immune system. Research indicates that its depletion is a hallmark of Crohn's disease and Ulcerative Colitis. Therapeutic administration helps restore the Treg/Th17 balance and reduces systemic oxidative stress via glutathione production.
Eubacterium limosum possesses the rare ability to metabolize dietary precursors of TMAO (trimethylamine N-oxide), a known driver of arterial plaque formation. Intercepting these precursors offers a microbial-based strategy for cardiovascular disease prevention.
Emerging studies suggest that Eubacterium species influence neuroinflammation. Preclinical data indicate potential applications in Multiple Sclerosis and Parkinson's Disease research by stabilizing the intestinal barrier and preventing "leaky gut" associated neurotoxicity.
Why Partner With Us?
Deep Anaerobic Expertise
We specialize in the "unculturable," maintaining rigorous anaerobic conditions from isolation to delivery.
Regulatory Alignment
All preclinical data is generated following Good Laboratory Practice principles, ensuring a smooth transition to IND (Investigational New Drug) filings.
Integrated Multi-omics
We don't just provide numbers; we provide insights by correlating microbial abundance with host transcriptomics and metabolomics.
State-of-the-Art Facility
Our labs are equipped with the latest sequencers, anaerobic workstations, and gnotobiotic animal suites.
Partner With Us Today
The potential of Eubacterium spp. to revolutionize the treatment of metabolic and inflammatory diseases is unparalleled. As these "keystone" bacteria take center stage in the Live Biotherapeutic industry, having a research partner that understands their complex anaerobic requirements and functional mechanisms is vital. Our company stands at the forefront of this frontier, providing the precision tools and scientific rigor necessary to turn microbial potential into clinical success.
Are you ready to accelerate your microbiome pipeline? Whether you are a biotech startup or an established pharmaceutical firm, our team is ready to provide the high-quality data you need to advance your Eubacterium-based candidates. Contact our scientific consultants today for a project-specific proposal and take the first step toward the future of biotherapeutics.
Is Eubacterium hallii now called Anaerobutyricum hallii?
Yes. Recent phylogenetic reclassification has moved E. hallii to the genus Anaerobutyricum. However, in many therapeutic contexts, the keyword Eubacterium remains the industry standard. Our services cover all strains within this lineage.
Can you perform custom strain engineering for Eubacterium?
While Eubacterium species are notoriously difficult to modify, we offer gene editing and plasmid-based engineering services for certain strains like E. limosum to enhance metabolite production or safety profiles.
What is the typical timeline for a preclinical efficacy study?
Depending on the disease model, a typical in vivo study ranges from 8 to 14 weeks, including colonization verification and terminal analysis.
Online Inquiry
For Research Use Only. Not intended for use in
food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
